976-50-1

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-N-[3,5-bis(trifluoromethyl)phenyl]benzamide is utilized as a building block in the synthesis of various biologically active compounds and pharmaceutical drugs. Its unique structure allows for the development of new therapeutic agents with potential applications in treating a range of diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Amino-N-[3,5-bis(trifluoromethyl)phenyl]benzamide serves as an intermediate in the production of agrochemicals. Its chemical properties make it a valuable component in the formulation of pesticides, herbicides, and other agricultural chemicals that enhance crop protection and yield.
Used in Materials Science:
4-Amino-N-[3,5-bis(trifluoromethyl)phenyl]benzamide also finds application in materials science as a component in the development of new materials. Its unique properties can be leveraged to create innovative materials with specific characteristics, such as improved stability, reactivity, or other desirable traits, for use in various industrial applications.
Overall, the versatility of 4-Amino-N-[3,5-bis(trifluoromethyl)phenyl]benzamide makes it a valuable tool for researchers and manufacturers in multiple industries, driving innovation and advancement in the development of new products and technologies.

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 328-74-5 3,5-Bis-(trifluoromethyl)aniline 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors

BTK is an effective target for the treatment of B-cell malignant tumors and autoimmune diseases. In this work, a series of 2-phenyl pyrimidine derivatives were prepared and their preliminary in vitro activities on B-cell leukemia cells as well as the BTK enzyme were determined. The results showed that compound 11g displayed the best inhibitory activity on BTK with an inhibition rate of 82.76% at 100 nM and excellent anti-proliferation activity on three B-cell leukemia lines (IC50 = 3.66 μM, 6.98 μM, and 5.39 μM against HL60, Raji and Ramos, respectively). Besides, the flow cytometry analysis results indicated that 11g inhibited the proliferation of the Raji cells in a dose- and time-dependent manner, and blocked the Ramos cells at the G0/G1 phase, which is in accordance with the positive control ibrutinib. The mechanism investigation demonstrated that 11g could inhibit the phosphorylation of BTK and its downstream substrate phospholipase γ2 (PLCγ2). All these results showed that 11g was a promising lead compound that merited further optimization as a novel class of BTK inhibitor for the treatment of B-cell lymphoblastic leukemia.

2-phenylpyrimidine compounds, preparation method and medical application

The invention belongs to the field of medicines and particularly relates to 2-phenylpyrimidine compounds and pharmacologically-acceptable salts thereof and an isotope marker. The invention also discloses a pharmaceutical composition containing the substances and application of the pharmaceutical composition for treating diseases related with protein kinase activity, such as cancer and inflammation. (The formula is shown in the description).